Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial

医学 贝伐单抗 内科学 福尔菲里 伊立替康 彭布罗利珠单抗 肿瘤科 西妥昔单抗 奥沙利铂 临床终点 结直肠癌 人口 生活质量(医疗保健) 癌症 实体瘤疗效评价标准 氟尿嘧啶 无进展生存期 微卫星不稳定性 临床研究阶段 化疗 临床试验 环境卫生 化学 生物化学 免疫疗法 等位基因 护理部 基因 微卫星
作者
Thierry André,Mayur M. Amonkar,Josephine M. Norquist,Kai-Keen Shiu,Tae Won Kim,Benny Vittrup Jensen,Lars Henrik Jensen,Cornelis J.A. Punt,Denis Smith,Rocio García‐Carbonero,Isabel Sevilla,Christelle de la Fouchardière,Fernando Rivera,Elena Élez,Luis A. Díaz,Takayuki Yoshino,Eric Van Cutsem,Ping Yang,Mohammed Z.H. Farooqui,Dung T. Le
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:22 (5): 665-677 被引量:162
标识
DOI:10.1016/s1470-2045(21)00064-4
摘要

In the KEYNOTE-177 study, pembrolizumab monotherapy provided statistically significant and clinically meaningful improvements in progression-free survival versus chemotherapy as first-line treatment in patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer. To further support the efficacy and safety findings of the KEYNOTE-177 study, results of the health-related quality of life (HRQOL) analyses are reported here.KEYNOTE-177 is an open-label, randomised, phase 3 trial being done at 192 cancer centres in 23 countries, in patients aged 18 years and older with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer, with an Eastern Cooperative Oncology Group performance status of 0 or 1, and who had not received previous systemic therapy for metastatic disease. Eligible patients were randomly assigned (1:1) centrally by use of interactive voice response or integrated web response technology to receive pembrolizumab 200 mg intravenously every 3 weeks or investigator's choice chemotherapy (mFOLFOX6 [leucovorin, fluorouracil, and oxaliplatin] or FOLFIRI [leucovorin, fluorouracil, and irinotecan] intravenously every 2 weeks with or without intravenous bevacizumab or cetuximab). Patients and investigators were not masked to treatment assignment. The primary endpoints were progression-free survival (previously reported) and overall survival (data to be reported at the time of the final analysis). HRQOL outcomes were evaluated as prespecified exploratory endpoints. The analysis population comprised all randomly assigned patients who received at least one dose of study treatment and completed at least one HRQOL assessment. HRQOL outcomes were mean change from baseline to prespecified week 18 in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and EORTC Quality of Life Questionnaire-Colorectal 29 (EORTC QLQ-CR29) scale and item scores, and in the EuroQoL 5 Dimensions 3 Levels (EQ-5D-3L) visual analogue scale and health utility scores; the proportion of patients with improved, stable, or deteriorated scores from baseline to prespecified week 18 in EORTC QLQ-C30 scales and items; and time to deterioration in EORTC QLQ-C30 global health status/quality of life (GHS/QOL), physical functioning, social functioning, and fatigue scores and EORTC QLQ-CR29 urinary incontinence scores. The threshold for a small and clinically meaningful mean difference in EORTC QLQ-C30 score was 5-8 points. This study is registered with ClinicalTrials.gov, NCT02563002 and is ongoing; recruitment is closed.Between Feb 11, 2016, and Feb 19, 2018, 307 patients were enrolled and randomly assigned to receive pembrolizumab (n=153) or chemotherapy (n=154). The HRQOL analysis population comprised 294 patients (152 receiving pembrolizumab and 142 receiving chemotherapy). As of Feb 19, 2020, median time from randomisation to data cutoff was 32·4 months (IQR 27·7-37·8). Least squares mean (LSM) change from baseline to prespecified week 18 showed a clinically meaningful improvement in EORTC QLQ-C30 GHS/QOL scores with pembrolizumab versus chemotherapy (between-group LSM difference 8·96 [95% CI 4·24-13·69]; two-sided nominal p=0·0002). Median time to deterioration was longer with pembrolizumab versus chemotherapy for GHS/QOL (hazard ratio 0·61 [95% CI 0·38-0·98]; one-sided nominal p=0·019), physical functioning (0·50 [95% CI 0·32-0·81]; one-sided nominal p=0·0016), social functioning (0·53 [95% CI 0·32-0·87]; one-sided nominal p=0·0050), and fatigue scores (0·48 [95% CI 0·33-0·69]; one-sided nominal p<0·0001).Pembrolizumab monotherapy led to clinically meaningful improvements in HRQOL compared with chemotherapy in patients with previously untreated microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer. These data, along with the previously reported clinical benefits, support pembrolizumab as a first-line treatment option for this population.Merck Sharp & Dohme, a subsidiary of Merck & Co, Kenilworth, NJ, USA.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
传奇3应助1122采纳,获得10
1秒前
大饼卷肉发布了新的文献求助10
1秒前
1秒前
白日梦发布了新的文献求助10
1秒前
2秒前
牧夜白完成签到,获得积分10
2秒前
负责的爆米花完成签到,获得积分10
2秒前
清脆映真发布了新的文献求助10
2秒前
汉堡包应助cyw采纳,获得10
3秒前
MJ完成签到,获得积分10
3秒前
FashionBoy应助大饼卷肉采纳,获得10
3秒前
3秒前
4秒前
Ausna完成签到,获得积分10
4秒前
紫定能行完成签到,获得积分20
4秒前
4秒前
菜萝卜发布了新的文献求助10
5秒前
5秒前
鹏鹏哥发布了新的文献求助30
5秒前
量子星尘发布了新的文献求助10
6秒前
少年旭发布了新的文献求助10
6秒前
还没想好发布了新的文献求助10
6秒前
紫紫完成签到,获得积分10
7秒前
7秒前
Ing发布了新的文献求助10
8秒前
小璐璐呀发布了新的文献求助10
8秒前
9秒前
大饼卷肉完成签到,获得积分10
9秒前
传奇3应助谦让雨柏采纳,获得10
9秒前
方方发布了新的文献求助10
10秒前
鲤鱼睿渊完成签到,获得积分10
10秒前
10秒前
思源应助demonox采纳,获得10
10秒前
11秒前
11秒前
跳不起来的大神完成签到 ,获得积分10
12秒前
tq发布了新的文献求助10
12秒前
HHHHHH完成签到 ,获得积分20
12秒前
我是老大应助tiam采纳,获得10
12秒前
隐形曼青应助溯流光采纳,获得10
13秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3974856
求助须知:如何正确求助?哪些是违规求助? 3519400
关于积分的说明 11198085
捐赠科研通 3255563
什么是DOI,文献DOI怎么找? 1797860
邀请新用户注册赠送积分活动 877208
科研通“疑难数据库(出版商)”最低求助积分说明 806219